Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092036 | 0.89 | MAPT (0.54) | LMNAALOX15USP2MTORPIK3CB | |
| SCHEMBL3098002 | 0.87 | PIK3CB (0.49) | LMNAMTORPIK3CBPIK3CGAKT1 | |
| SCHEMBL3087828 | 0.85 | ALDH1A1 (0.56) | MTORPIK3CBPIK3CGAKT1PIK3CA | |
| SCHEMBL3074245 | 0.85 | PIK3CA (0.52) | LMNAMTORPIK3CBPIK3CGAKT1 | |
| SCHEMBL3078390 | 0.84 | CKS1B (0.51) | MTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL3087547 | 0.83 | ALPL (0.47) | LMNAUSP2MTORPIK3CBPIK3CG | |
| SCHEMBL3091720 | 0.83 | PIK3CG (0.50) | MTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL3079692 | 0.83 | MCOLN2 (0.50) | MTORPIK3CBPIK3CGPIK3CAALDH1A1 | |
| SCHEMBL3632905 | 0.83 | PIK3CG (0.49) | MTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL3084494 | 0.82 | PIK3CA (0.46) | LMNAMTORPIK3CBPIK3CGAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| EP-2150255-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | Smithkline Beecham Corporation (US) | 2010-02-10 | — | — | EP | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | LMNA 4815/4885ALOX15 2065/4885USP2 4182/4885 |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | LMNA 4815/4885ALOX15 2065/4885USP2 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.